Navigation Links
Silenced genes as a warning sign of blood cancer
Date:8/4/2009

In many types of cancer, parts of the genetic material of tumor cells are switched off by chemical labels called methyl groups. This kind of methyl labeling ranges among the epigenetic changes that do not change the sequence of DNA building blocks. Such labels are found particularly often in genes which act as important inhibitors of pathogenic cell growth.

Cancer researchers do not know why healthy cells and cancer cells differ in their methylation patterns and why it is particularly the cancer inhibitors that are frequently switched off. The study of these questions is a very promising area of research, because there are drugs available that can prevent the attachment of methyl groups or other epigenetic changes and, thus, at least delay the onset of cancer.

Professor Dr. Christoph Plass at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) has investigated, jointly with colleagues from the Ohio State University in Columbus, U.S.A., the processes leading to the different methyl labels in cancer cells. A key question is when the first labels occur in the development of cancer. In their recently published study the investigators used mice affected by chronic lymphocytic leukemia as a model for studying the disease.

The researchers investigated the genetic material of these mice at regular intervals from birth. They discovered first cancer-typical methylation patterns in mice that were only three months old. This means that deviations in methylation occur long before the first signs of disease appear. These were not observed before the animals were thirteen months old. Moreover, the researchers were able to show that methylation patterns in murine DNA are largely corresponding to those found in humans suffering from leukemia. This confirms that the mouse model is suitable for studying the disease.

"Since first deviations in methylation occur so early in mice, we should find out whether this is also true for humans. If so, an early methylation test in high-risk individuals could provide clues about a developing cancer," Christoph Plass says. In this case, preventive medical intervention might be possible. Drugs preventing methyl group attachment might delay the onset of cancer. First clinical studies have already been started to check this. "This is probably most effective in a very early phase of methylation," Plass explains. The researchers believe that the first chemically deactivated genes trigger whole cascades of changes in the genetic material which can hardly be controlled at a later stage.

Keyword: Epigenetics

The cells of the roughly 200 different tissues of the human body can fulfill their special tasks only by regulating the activity of their respective genes very specifically. Although every single gene is equipped with its own control elements, this is not enough for complex coordination. There is a second code that serves as an additional control level. In addition to the genetic switches that are directly integrated in the genetic material, the DNA, genes can also be switched on or off by chemical labeling of the DNA or the DNA packaging proteins. The most common of such epigenetic mutations is the attachment of methyl groups. The effect of these small chemical compounds is that a gene can no longer be read and translated into proteins.

Unlike genetic mutations, which permanently change the sequence of the DNA building blocks, all epigenetic mutations are reversible and, therefore, potential target structures of appropriate drugs.


'/>"/>

Contact: Dr. Sibylle Kohlstaedt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Related medicine news :

1. Pathway links inflammation, angiogenesis and breast cancer
2. Traffic Fumes Plus Genes Boosts Kids Asthma Risk
3. New Database to Help Speed Search for Bipolar Disorder Genes
4. Is Perfect Pitch All in the Genes?
5. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
6. Genes Boost Risk for Rheumatoid Arthritis, Lupus
7. The genes involved in rheumatoid arthritis identified
8. If you think cancer genes are simple, you dont know JAK
9. Test for lung cancer looks for discomforting quiet among protective genes
10. Hushed Genes Might Mean Higher Lung Cancer Risk
11. EURYI project to understand how the brain wires during embryogenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016  The National Pharmaceutical Council (NPC) ... health policy research organization as its newest member.  ... senior vice president and chief scientific officer, Mallinckrodt ... the NPC Board of Directors. ... has joined us in support of our efforts ...
(Date:6/23/2016)... -- Delcath Systems, Inc. (NASDAQ: DCTH ), a ... of primary and metastatic liver cancers, announces that the ... www.againsttheodds.eu - has been awarded a silver medal ... The website was developed as an education ... who are coping with the devastating diagnosis of cancer ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. Stock-Callers.com has initiated coverage on the following equities: ... (NASDAQ: AMAG ), IDEXX Laboratories Inc. (NASDAQ: ... ADRO ). Learn more about these stocks by accessing their ...
Breaking Medicine Technology: